Letter from the Editor-in-Chief

Molecular Profiling Should Now Be Routine Practice in Patients with CCA

September/October 2021, Vol 2, No 3 — October 7, 2021

This issue of CCA News features yet another exciting FDA approval for cholangiocarcinoma (CCA), ivosidenib, which was recently approved for CCA with IDH1 mutation. This is the third drug approved for CCA in the past 2 years, highlighting the critical role of molecular profiling in this cancer. Up to 20% of patients with intrahepatic CCA have IDH1 mutation, and the ClarIDHy phase 3 study demonstrated improvement in progression-free survival with ivosidenib versus placebo for chemorefractory disease. The FDA also approved the Oncomine Dx Target Test for IDH1 mutations.

Continuing Progress in Cholangiocarcinoma and Bilary Tract Cancers

By Milind M. Javle, MD

Letter from the Editor-in-Chief

March 2021, Vol 2, No 1 — April 13, 2021

Dear Colleagues, It gives me great pleasure to introduce the March issue of CCA News. Once again, we have several recent developments in cholangiocarcinoma (CCA) clinical research, and these have been reviewed by leaders in the field.

Takeaways from the 2020 Cholangiocarcinoma Summit

By Milind M. Javle, MD

Letter from the Editor-in-Chief

December 2020, Vol 1, No 3 — January 5, 2021

In this last issue for the year, we are highlighting the proceedings of the Second Annual Cholangiocarcinoma (CCA) Summit, which was conducted on October 22-23, 2020. This summit attracted a wide, multidisciplinary audience and was very interactive, despite being a virtual event. An important focus for this meeting was the emergence of molecular targets in CCA and early successes seen with precision medicine in this disease. Many of the key presentations from the summit are included in the current issue and are highlighted below.

Important Advances in Cholangiocarcinoma Management

By Milind M. Javle, MD

Letter from the Editor-in-Chief

October 2020, Vol 1, No 2 — October 29, 2020

While the COVID-19 pandemic rages throughout the world, patients, providers, and healthcare advocates are learning to survive in an alternative (virtual) world that is likely to change the face of medicine forever. Cholangiocarcinoma (CCA) is a complex disease that requires multidisciplinary care. Virtual clinic visits and online tumor boards and symposia represent just a few of the countless innovations introduced over the past year.

Welcome to the Inaugural Issue of CCA News

By Milind M. Javle, MD

Letter from the Editor-in-Chief

August 2020, Vol 1, No 1 — September 10, 2020

It is my great pleasure to launch the inaugural issue of CCA News, an important new publication highlighting the latest research and development in cholangiocarcinoma (CCA). I am proud that we now have a focused publication on biliary tract cancers and am humbled to serve as the first editor-in-chief.

Letter from the Editor-in-Chief

Subscribe Today!

I'd like to receive:

Stay In The Know

Letter from the Editor-in-Chief

Page 2 of 2

Subscribe Today!

I'd like to receive:

Stay In The Know